Persistent Cryoglobulinaemia After HCV Cure: Implications for Kidney Transplantation

Clicks: 10
ID: 337744
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #213 of 228 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 228 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Direct-acting antivirals cure most patients with chronic hepatitis C virus (HCV) infection, but recovery from HCV-associated mixed cryoglobulinaemia is less uniform: clinical and immunologic responses may be incomplete, delayed or followed by relapse. Cryoglobulins, rheumatoid factor, hypocomplementaemia and residual B-cell clones frequently persist after sustained virologic response (SVR), and it is often unclear whether these findings reflect ongoing cryoglobulinaemic disease, slowly resolving immunologic abnormality or, where organ dysfunction persists, irreversible chronic damage. The distinction is consequential in kidney transplant candidates, in whom persistent abnormalities may raise concern about transplant timing, recurrent cryoglobulinaemic glomerulonephritis (CryoGN) and the use of pretransplant rituximab or plasma exchange, yet transplant-specific evidence is minimal. This narrative review examines evidence relevant to individualised pretransplant assessment, prompted by a patient with advanced chronic kidney disease, persistent type II cryoglobulinaemia and predominantly chronic biopsy findings who sought advice about future transplantation. We distinguish direct transplant observations from non-transplant post-SVR data, treatment evidence for active disease, and expert-derived proposals. Direct evidence in HCV-cured patients with cryoglobulinaemic kidney disease is sparse, and comparative evidence for pretransplant immunomodulation for isolated serologic persistence is lacking. We propose an unvalidated expert framework comprising active disease, uncertain activity, and clinical remission with persistent serologic abnormalities; these are provisional clinical descriptions rather than validated risk categories or eligibility criteria. Assessment should centre on organ activity, clinically significant clonal disease and follow-up requirements. In our view, persistent serologic abnormalities alone, in the absence of objective organ activity or clinically significant clonal disease, should not be the determinant of transplant eligibility.
Reference Key
openalex_W7224648654 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Huong Thi Nguyen, Nguyen The Thoi, Thuc Thi Minh Nguyen, Thuy Thi Lan Le, Tu Tuan Tran, Dung Trung Nghiem
Are you one of these authors? Claim your profile
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag388
URL
https://doi.org/10.1093/ckj/sfag388
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.